(S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

US9993449B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9993449-B2
Application numberUS-201715586730-A
CountryUS
Kind codeB2
Filing dateMay 4, 2017
Priority dateOct 9, 2015
Publication dateJun 12, 2018
Grant dateJun 12, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.

First claim

Opening claim text (preview).

We claim: 1. A method for treatment of psychological and neurological disorders, said method comprising administering to a mammalian subject in need thereof an effective amount of a compound of a formula wherein each of R1 and R2 is independently selected from H, F, Cl, Br and I, providing at least one of R1 and R2 is not H, or a salt thereof. 2. The method of claim 1 wherein said neurological disorder is selected from epilepsy, infantile spasms, partial seizures, complex partial seizures, secondary generalized seizures, tonic-clonic seizures, succinic semialdehyde dehydrogenase deficiency (SSADHD), infantile spasms in West's syndrome, Lennox-Gastaut syndrome, tubulous sclerosis, Tourette's syndrome, movement disorders, fibromyalgia, neuropathic pain, migraine related to epilepsy, restless leg syndrome and post traumatic stress disorder, addiction, obesity, obsessive compulsive disorder and Alzheimer's disease and combinations of the foregoing. 3. The method of claim 1 wherein said psychological disorder selected from general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders and combinations thereof. 4. The method of claim 1 wherein each of R 1 and R 2 is F. 5. The method of claim 1 wherein said compound is provided in a pharmaceutical composition. 6. A method for treatment of a neurological disorder comprising administering to a subject in need thereof a compound of a formula or a pharmaceutically acceptable salt thereof. 7. The method of claim 6 wherein the neurological disorder is selected from epilepsy, infantile spasms, partial seizures, complex partial seizures, secondary generalized seizures, tonic-clonic seizures, succinic semialdehyde dehydrogenase deficiency (SSADHD), infantile spasms in West's syndrome, Lennox-Gastaut syndrome, or tubulous sclerosis. 8. The method of claim 6 wherein the neurological disorder is epilepsy. 9. The method of claim 6 wherein the neurological disorder is infantile spasms. 10. The method of claim 6 wherein the neurological disorder is partial seizures. 11. The method of claim 6 wherein the neurological disorder is Lennox-Gastaut syndrome. 12. The method of claim 6 wherein the neurological disorder is tubulous sclerosis. 13. The method of claim 6 wherein said neurological disorder is selected from Tourette's syndrome, movement disorders, fibromyalgia, neuropathic pain, migraine related to epilepsy, restless leg syndrome and post traumatic stress disorder, addiction, obesity, obsessive compulsive disorder or Alzheimer's disease. 14. The method of claim 6 wherein said neurological disorder is addiction. 15. The method of claim 6 wherein said neurological disorder is substance addiction. 16. The method of claim 6 wherein said neurological disorder is obsessive-compulsive disorder. 17. The method of claim 6 wherein said neurological disorder is Alzheimer's disease.

Assignees

Inventors

Classifications

  • Centrally acting analgesics, e.g. opioids · CPC title

  • for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

  • Opioid-abuse · CPC title

  • Antiepileptics; Anticonvulsants · CPC title

  • Anorexiants; Antiobesity agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9993449B2 cover?
Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.
Who is the assignee on this patent?
Univ Northwestern
What technology area does this patent fall under?
Primary CPC classification A61K31/196. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).